BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002;95:506-512. [PMID: 12209742 DOI: 10.1002/cncr.10709] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Thoms J, Goda JS, Zlotta AR, Fleshner NE, van der Kwast TH, Supiot S, Warde P, Bristow RG. Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol 2011;8:107-13. [DOI: 10.1038/nrclinonc.2010.207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
2 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
3 Awolaran O, Brooks SA, Lavender V. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. The Breast 2016;30:156-71. [DOI: 10.1016/j.breast.2016.09.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
4 Llera AS, Girotti MR, Benedetti LG, Podhajcer OL. Matricellular proteins and inflammatory cells: A task force to promote or defeat cancer? Cytokine & Growth Factor Reviews 2010;21:67-76. [DOI: 10.1016/j.cytogfr.2009.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2005;31:555-8. [PMID: 15922893 DOI: 10.1016/j.ejso.2005.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
6 Li C, Zang T, Wrobel K, Huang JT, Nabi G. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Anal Bioanal Chem 2015;407:3393-404. [PMID: 25724369 DOI: 10.1007/s00216-015-8569-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
7 Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, Berking C. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol 2012;26:1084-91. [PMID: 21838826 DOI: 10.1111/j.1468-3083.2011.04210.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
8 Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006;169:233-246. [PMID: 16816376 DOI: 10.2353/ajpath.2006.051152] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
9 Lukacova S, Overgaard J, Alsner J, Horsman MR. Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiotherapy and Oncology 2006;80:165-71. [DOI: 10.1016/j.radonc.2006.07.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
10 Johnson GA, Burghardt RC, Bazer FW. Osteopontin: a leading candidate adhesion molecule for implantation in pigs and sheep. J Anim Sci Biotechnol 2014;5:56. [PMID: 25671104 DOI: 10.1186/2049-1891-5-56] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
11 Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget 2017;8:31554-67. [PMID: 28404939 DOI: 10.18632/oncotarget.15767] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
12 Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010;5:e15074. [PMID: 21152079 DOI: 10.1371/journal.pone.0015074] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
13 Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, Ezura Y, Nakashima K, Noda M. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 2007;101:979-86. [PMID: 17390343 DOI: 10.1002/jcb.21298] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
14 Tilli TM, Silva EA, Matos LC, Faget DV, Dias BF, Vasconcelos JS, Yokosaki Y, Gimba ER. Osteopontin is a tumor autoantigen in prostate cancer patients. Oncol Lett 2011;2:109-14. [PMID: 22870138 DOI: 10.3892/ol.2010.211] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
15 Buijs JT, Stayrook KR, Guise TA. The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep 2012;1:96. [PMID: 23951484 DOI: 10.1038/bonekey.2012.96] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
16 Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8:212-226. [PMID: 18292776 DOI: 10.1038/nrc2345] [Cited by in Crossref: 305] [Cited by in F6Publishing: 291] [Article Influence: 21.8] [Reference Citation Analysis]
17 Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21. [DOI: 10.1016/s1535-6108(03)00215-0] [Cited by in Crossref: 754] [Cited by in F6Publishing: 458] [Article Influence: 39.7] [Reference Citation Analysis]
18 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71-81. [PMID: 20205680 DOI: 10.2174/156652410791065381] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
19 Zhao J, Lu B, Xu H, Tong X, Wu G, Zhang X, Liang A, Cong W, Dai J, Wang H. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology. 2008;48:265-275. [PMID: 18537194 DOI: 10.1002/hep.22280] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
20 Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Azuma M, Yara S, Shinzato T, Higa F, Tateyama M, Kadota J, Mukae H, Kohno S, Uede T, Saito A. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003;167:1355-9. [PMID: 12574077 DOI: 10.1164/rccm.200209-1113OC] [Cited by in Crossref: 69] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
21 Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005;54:1254-62. [PMID: 16099792 DOI: 10.1136/gut.2004.048298] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 5.4] [Reference Citation Analysis]
22 Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Osteopontin: it’s role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005;57:441-447. [PMID: 16012053 DOI: 10.1080/15216540500159424] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
23 Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709-717. [PMID: 16786357 DOI: 10.1007/s00432-006-0119-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
24 Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One 2012;7:e47901. [PMID: 23112867 DOI: 10.1371/journal.pone.0047901] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
25 Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 2012;31:26. [PMID: 22444159 DOI: 10.1186/1756-9966-31-26] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
26 Arai M, Yokosuka O, Kanda T, Fukai K, Imazeki F, Muramatsu M, Seki N, Miyazaki M, Ochiai T, Hirasawa H. Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol. 2006;41:102-110. [PMID: 16373283 DOI: 10.1080/00365520510024061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
27 Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomark Med 2013;7:831-41. [PMID: 24266816 DOI: 10.2217/bmm.13.112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
28 Ohno K, Nishimori H, Yasoshima T, Kamiguchi K, Hata F, Fukui R, Okuya K, Kimura Y, Denno R, Kon S. Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model. Surg Today. 2010;40:347-356. [PMID: 20339989 DOI: 10.1007/s00595-009-4082-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM. Plasma osteopontin in acute liver failure. Cytokine. 2015;73:270-276. [PMID: 25802196 DOI: 10.1016/j.cyto.2015.02.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
30 Wu X, Gong S, Roy-Burman P, Lee P, Culig Z. Current mouse and cell models in prostate cancer research. Endocr Relat Cancer 2013;20:R155-70. [PMID: 23580590 DOI: 10.1530/ERC-12-0285] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 6.9] [Reference Citation Analysis]
31 Valta MP, Tuomela J, Vuorikoski H, Loponen N, Väänänen RM, Pettersson K, Väänänen HK, Härkönen PL. FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem. 2009;107:769-784. [PMID: 19415685 DOI: 10.1002/jcb.22175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
32 Li Y, Li L, Wang JT, Kan X, Lu JG. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 2012;29:1429-34. [PMID: 21706367 DOI: 10.1007/s12032-011-0012-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
33 Christensen E, Evans KR, Ménard C, Pintilie M, Bristow RG. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Rev 2008;27:375-85. [PMID: 18427732 DOI: 10.1007/s10555-008-9139-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
34 Lerner MB, D'Souza J, Pazina T, Dailey J, Goldsmith BR, Robinson MK, Johnson AT. Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers. ACS Nano 2012;6:5143-9. [PMID: 22575126 DOI: 10.1021/nn300819s] [Cited by in Crossref: 72] [Cited by in F6Publishing: 58] [Article Influence: 7.2] [Reference Citation Analysis]
35 Buijs JT, Stayrook KR, Guise TA. TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron 2011;4:261-81. [PMID: 21748439 DOI: 10.1007/s12307-011-0075-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
36 Sun J, Xu HM, Zhou HJ, Dong QZ, Zhao Y, Fu LY, Hei ZY, Ye QH, Ren N, Jia HL. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1-7. [PMID: 19593583 DOI: 10.1007/s00432-009-0629-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
37 Lai KP, Yamashita S, Vitkus S, Shyr CR, Yeh S, Chang C. Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol 2012;26:52-66. [PMID: 22135068 DOI: 10.1210/me.2011-1189] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
38 Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130:497-513. [PMID: 15205947 DOI: 10.1007/s00432-004-0572-9] [Cited by in Crossref: 105] [Cited by in F6Publishing: 129] [Article Influence: 5.8] [Reference Citation Analysis]
39 Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782-789. [PMID: 17148500 DOI: 10.1136/gut.2006.109868] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]
40 Saleh S, Thompson DE, McConkey J, Murray P, Moorehead RA. Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. BMC Cancer 2016;16:359. [PMID: 27282619 DOI: 10.1186/s12885-016-2396-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
41 Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, Yau TC, Lo OS, Foo DC, Poon JT, Poon RT, Pang RW, Law WL. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One 2015;10:e0126219. [PMID: 25961724 DOI: 10.1371/journal.pone.0126219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
42 Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91. [DOI: 10.1182/blood-2003-11-3839] [Cited by in Crossref: 233] [Cited by in F6Publishing: 206] [Article Influence: 12.9] [Reference Citation Analysis]
43 Aresta A, Calvano CD, Palmisano F, Zambonin CG, Monaco A, Tommasi S, Pilato B, Paradiso A. Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2008;46:157-64. [DOI: 10.1016/j.jpba.2007.10.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
44 Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007;9:1237-94. [PMID: 17571959 DOI: 10.1089/ars.2007.1623] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
45 Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer: Osteopontin as a biomarker for ovarian cancer. Journal of Obstetrics and Gynaecology Research 2006;32:309-14. [DOI: 10.1111/j.1447-0756.2006.00403.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
46 Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 2005;96:803-5. [PMID: 16153205 DOI: 10.1111/j.1464-410X.2005.05716.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
47 Salehi F, Jalali S, Alkins R, Lee JI, Lwu S, Burrell K, Gentili F, Croul S, Zadeh G. Proteins involved in regulating bone invasion in skull base meningiomas. Acta Neurochir (Wien) 2013;155:421-7. [PMID: 23238945 DOI: 10.1007/s00701-012-1577-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
48 Kapoor P, Suva LJ, Welch DR, Donahue HJ. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 2008;103:30-41. [DOI: 10.1002/jcb.21382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
49 Akbalik ME, Sagsoz H, Erdogan S. Osteopontin expression in the intestine of chukar partridge (Alectoris chukar, Gray, 1830). Animal Biol 2015;65:287-98. [DOI: 10.1163/15707563-00002477] [Reference Citation Analysis]
50 Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS, Fu WM. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 2013;83:968-77. [PMID: 23434829 DOI: 10.1124/mol.112.082339] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
51 Noda M, Denhardt DT. Osteopontin. Principles of Bone Biology. Elsevier; 2008. pp. 351-66. [DOI: 10.1016/b978-0-12-373884-4.00037-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
52 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, Chen CH, Huang CC. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 2008;30:776-81. [PMID: 18228527 DOI: 10.1002/hed.20783] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
53 Zhou Q, Gui S, Zhou Q, Wang Y. Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoS One 2014;9:e101132. [PMID: 24992189 DOI: 10.1371/journal.pone.0101132] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
54 Suzuki S, Yuan H, Hirata-Tsuchiya S, Yoshida K, Sato A, Nemoto E, Shiba H, Yamada S. DMP-1 promoter-associated antisense strand non-coding RNA, panRNA-DMP-1, physically associates with EGFR to repress EGF-induced squamous cell carcinoma migration. Mol Cell Biochem 2021;476:1673-90. [PMID: 33420898 DOI: 10.1007/s11010-020-04046-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009;45:798-802. [PMID: 19213594 DOI: 10.1016/j.oraloncology.2008.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
56 Duquesnay R, Wright C, Aziz AA, Stamp GW, Trew GH, Margara RA, White JO. Infertile women with isolated polycystic ovaries are deficient in endometrial expression of osteopontin but not αvβ3 integrin during the implantation window. Fertility and Sterility 2009;91:489-99. [DOI: 10.1016/j.fertnstert.2007.11.063] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
57 Trotter TN, Li M, Pan Q, Peker D, Rowan PD, Li J, Zhan F, Suva LJ, Javed A, Yang Y. Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood 2015;125:3598-608. [PMID: 25862559 DOI: 10.1182/blood-2014-12-613968] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
58 Sutherland M, Gordon A, Shnyder SD, Patterson LH, Sheldrake HM. RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) 2012;4:1106-45. [PMID: 24213501 DOI: 10.3390/cancers4041106] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
59 Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y, Hatakeyama K. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol. 2008;39:1777-1783. [PMID: 18701136 DOI: 10.1016/j.humpath.2008.05.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
60 Briese J, Schulte HM, Bamberger CM, L??ning T, Bamberger A. Expression Pattern of Osteopontin in Endometrial Carcinoma: Correlation With Expression of the Adhesion Molecule CEACAM1: . International Journal of Gynecological Pathology 2006;25:161-9. [DOI: 10.1097/01.pgp.0000189243.49522.ae] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
61 Mandelin J, Lin EC, Hu DD, Knowles SK, Do KA, Wang X, Sage EH, Smith JW, Arap W, Pasqualini R. Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin. Cancer 2009;115:1753-64. [PMID: 19224553 DOI: 10.1002/cncr.24170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
62 Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012;107:840-6. [PMID: 22871886 DOI: 10.1038/bjc.2012.345] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
63 El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009;69:3695-703. [PMID: 19351854 DOI: 10.1158/0008-5472.CAN-08-2958] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
64 O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003;14:479-88. [PMID: 14563350 DOI: 10.1016/s1359-6101(03)00055-8] [Cited by in Crossref: 100] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
65 Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs. Clinical Chemistry 2009;55:895-903. [DOI: 10.1373/clinchem.2008.117465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
66 Park MG, Oh MM, Yoon JH, Park JY, Park HS, Moon DG, Yoon DK. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study. Kaohsiung J Med Sci 2012;28:526-30. [PMID: 23089317 DOI: 10.1016/j.kjms.2012.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
67 Chen S, Boda SK, Batra SK, Li X, Xie J. Emerging Roles of Electrospun Nanofibers in Cancer Research. Adv Healthc Mater 2018;7:e1701024. [PMID: 29210522 DOI: 10.1002/adhm.201701024] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
68 Trotter TN, Yang Y. Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol 2016;52-54:301-14. [PMID: 26807761 DOI: 10.1016/j.matbio.2016.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
69 Lim W, Song G. Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. J Cancer Prev 2013;18:209-20. [PMID: 25337548 DOI: 10.15430/jcp.2013.18.3.209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
70 Gebri E, Kiss A, Tóth F, Hortobágyi T. Salivary Osteopontin as a Potential Biomarker for Oral Mucositis. Metabolites 2021;11:208. [PMID: 33808230 DOI: 10.3390/metabo11040208] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5:111-122. [PMID: 21516514 DOI: 10.1007/s12079-011-0130-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
72 Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-40. [DOI: 10.1002/pros.20540] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
73 Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair with cancers. J Oncol 2012;2012:351089. [PMID: 22481923 DOI: 10.1155/2012/351089] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
74 Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 2008;56:57-66. [PMID: 17938278 DOI: 10.1369/jhc.7A7325.2007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
75 Dos Santos ES, Ramos JC, Roza ALOC, Mariz BALA, Paes Leme AF. The role of osteopontin in oral cancer: A brief review with emphasis on clinical applications. Oral Dis 2020. [PMID: 33188646 DOI: 10.1111/odi.13716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Tang X, Wen J, Zhang X, Jiang D. Association between decreased osteopontin and acute mountain sickness upon rapid ascent to 3500 m among young Chinese men. Journal of Travel Medicine 2018;25. [DOI: 10.1093/jtm/tay075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
77 Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 2010;67:114-9. [PMID: 19376608 DOI: 10.1016/j.lungcan.2009.03.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
78 Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology. 2005;68:285-292. [PMID: 16015046 DOI: 10.1159/000086961] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
79 Hsieh YH, Margaret Juliana M, Ho KJ, Kuo HC, van der Heyde H, Elmets C, Chang PL. Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells. Int J Cancer 2012;131:322-33. [PMID: 21826648 DOI: 10.1002/ijc.26359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
80 Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 2003;20:77-84. [PMID: 12650610 DOI: 10.1023/a:1022550721404] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
81 Hernandez RK, Adhia A, Wade SW, O'Connor E, Arellano J, Francis K, Alvrtsyan H, Million RP, Liede A. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol 2015;7:335-45. [PMID: 26229504 DOI: 10.2147/CLEP.S85496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
82 Hartman O, Zhang C, Adams EL, Farach-Carson MC, Petrelli NJ, Chase BD, Rabolt JF. Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model. Biomaterials 2010;31:5700-18. [PMID: 20417554 DOI: 10.1016/j.biomaterials.2010.03.017] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 8.4] [Reference Citation Analysis]
83 Zhao L, Wang Y, Qu N, Huang C, Chen L. Significance of Plasma Osteopontin Levels in Patients with Bladder Urothelial Carcinomas. Mol Diagn Ther 2012;16:311-6. [DOI: 10.1007/s40291-012-0005-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
84 Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ, Sodek J. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 2011;132:39-48. [PMID: 20722758 DOI: 10.1111/j.1365-2567.2010.03335.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
85 Curtis KJ, Schiavi J, Mc Garrigle MJ, Kumar V, McNamara LM, Niebur GL. Mechanical stimuli and matrix properties modulate cancer spheroid growth in three-dimensional gelatin culture. J R Soc Interface 2020;17:20200568. [PMID: 33323051 DOI: 10.1098/rsif.2020.0568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007;14:3419-3427. [PMID: 17896150 DOI: 10.1245/s10434-007-9564-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
87 Zhou Y, Romson J, Emmer Å. An antibody-free sample pretreatment method for osteopontin combined with MALDI-TOF MS/MS analysis. PLoS One 2019;14:e0213405. [PMID: 30845167 DOI: 10.1371/journal.pone.0213405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Yu A, Guo K, Qin Q, Xing C, Zu X. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis. Biosci Rep 2021:BSR20203531. [PMID: 33635319 DOI: 10.1042/BSR20203531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877-1881. [PMID: 15138464 DOI: 10.1038/sj.bjc.6601839] [Cited by in Crossref: 298] [Cited by in F6Publishing: 281] [Article Influence: 16.6] [Reference Citation Analysis]
90 Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007;7:64. [PMID: 17430594 DOI: 10.1186/1471-2407-7-64] [Cited by in Crossref: 334] [Cited by in F6Publishing: 311] [Article Influence: 22.3] [Reference Citation Analysis]
91 Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643-652. [PMID: 17479289 DOI: 10.1007/s00432-007-0215-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
92 Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-6371. [PMID: 17452979 DOI: 10.1038/sj.onc.1210463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 128] [Article Influence: 8.3] [Reference Citation Analysis]
93 Sasaroli D, Coukos G, Scholler N. Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 2009;3:275-88. [PMID: 19684876 DOI: 10.2217/bmm.09.21] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
94 Johnson GA, Burghardt RC, Bazer FW, Spencer TE. Osteopontin: roles in implantation and placentation. Biol Reprod 2003;69:1458-71. [PMID: 12890718 DOI: 10.1095/biolreprod.103.020651] [Cited by in Crossref: 194] [Cited by in F6Publishing: 181] [Article Influence: 10.2] [Reference Citation Analysis]
95 Weber KL, Gebhardt MC. WHATʼS NEW IN MUSCULOSKELETAL ONCOLOGY: . The Journal of Bone and Joint Surgery-American Volume 2003;85:761-7. [DOI: 10.2106/00004623-200304000-00029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 Ruppender NS, Merkel AR, Martin TJ, Mundy GR, Sterling JA, Guelcher SA. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One 2010;5:e15451. [PMID: 21085597 DOI: 10.1371/journal.pone.0015451] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
97 Christensen B, Sørensen ES. Structure, function and nutritional potential of milk osteopontin. International Dairy Journal 2016;57:1-6. [DOI: 10.1016/j.idairyj.2016.02.034] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
98 Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549. [PMID: 12842083 DOI: 10.1016/s1535-6108(03)00132-6] [Cited by in Crossref: 1778] [Cited by in F6Publishing: 992] [Article Influence: 98.8] [Reference Citation Analysis]
99 Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer 2008;8:38. [PMID: 18237408 DOI: 10.1186/1471-2407-8-38] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
100 Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 2004;63:321-6. [PMID: 14972482 DOI: 10.1016/j.urology.2003.09.044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
101 Chabas D. [Osteopontin, a multi-faceted molecule]. Med Sci (Paris) 2005;21:832-8. [PMID: 16197900 DOI: 10.1051/medsci/20052110832] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
102 Sennels HP, Jacobsen S, Jensen T, Hansen MS, Østergaard M, Nielsen HJ, Sørensen S. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive protein. Scandinavian Journal of Clinical and Laboratory Investigation 2009;67:821-35. [DOI: 10.1080/00365510701432509] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]